Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-02-18FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Genus Lifesciences)
FDA approved the original application for a generic dorzolamide hydrochloride and timolol maleate combination to treat elevated intraocular …
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Open-Label Study of Safety of H1337 in Healthy Volunteers [Phase 1]
Open-label Phase 1 safety study of H1337 in healthy volunteers completed; Open-angle glaucoma and ocular hypertension are listed as the stud…
-
FDA approval · 2025-02-11FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Original Application (Somerset Therapeutics, LLC)
FDA approved a generic dorzolamide hydrochloride product under an Original Application by Somerset Therapeutics, LLC. Dorzolamide hydrochlor…
-
EMA approval · 2025-01-27EMA Authorised: Izba (travoprost) — Novartis Europharm Limited
The European Medicines Agency authorised Izba, a travoprost eye drop by Novartis Europharm Limited, for ocular hypertension and open-angle g…
-
FDA approval · 2025-01-24FDA Approved: ROCKLATAN — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for ROCKLATAN (netarsudil and latanoprost ophthalmic solution) from Alcon Laboratories, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients [Phase 2]
This notice reports the completion of a Phase 2 study evaluating QLS-111 in patients with primary open-angle glaucoma and ocular hypertensio…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 [Phase 2]
Phase 2 trial evaluating the safety and tolerability of two concentrations of QLS-101 in Sturge-Weber syndrome and glaucoma-related conditio…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) [Phase 2]
A Phase 2 safety and tolerability study of QLS-101 in adolescents with Sturge-Weber syndrome-related glaucoma due to elevated episcleral ven…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients [Phase 2]
Phase 2 clinical trial update for QLS-111 in combination with a prostaglandin analogue for open-angle glaucoma and ocular hypertension; the …
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). [Phase 2]
A Phase 2 trial comparing QLS-101 to Timolol Maleate Eye Drops in adults with high eye pressure due to primary open-angle glaucoma or ocular…
-
EMA withdrawal · 2024-12-17EMA Application withdrawn: Durysta (bimatoprost) — AbbVie Deutschland GmbH & Co. KG
The EMA has withdrawn the marketing authorization application for Durysta (bimatoprost) submitted by AbbVie Deutschland GmbH & Co. KG for op…
-
FDA approval · 2024-11-26FDA Approved: LATANOPROST — Original Application (Sagent Pharmaceuticals)
FDA approved the original application for latanoprost from Sagent Pharmaceuticals (a generic).
-
EMA approval · 2024-11-18EMA Authorised: Ganfort (bimatoprost;timolol) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Ganfort, a combination of bimatoprost and timolol, for glaucoma (open-angle) and ocular hypertensio…
-
EMA approval · 2024-11-18EMA Authorised: Lumigan (bimatoprost) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Lumigan (bimatoprost) for open-angle glaucoma and ocular hypertension, with AbbVie Deutschland GmbH & Co. KG as the marke…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt
A clinical trial update notes ongoing recruitment for evaluating the long-term safety and effectiveness of a modified suprachoroidal silicon…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety [Phase 4]
Phase 4 trial comparing preservative-free dorzolamide + timolol with preserved dorzolamide + timolol in open-angle glaucoma and ocular hyper…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS
A completed clinical trial evaluating the CATS TONOMETER PRISM device in LASIK subjects with glaucoma, ocular hypertension, and normal tensi…
-
CLINICAL_TRIALS research · 2024-10-31Clinical Trial Update: Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins
This clinical trial investigates inflammatory biomarkers on the ocular surface in patients with open-angle glaucoma or ocular hypertension w…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Performance of the Travoprost Intraocular Implant [Phase 2]
Phase 2 trial results for the travoprost intraocular implant targeting open-angle glaucoma and ocular hypertension have been posted.
-
FDA approval · 2024-10-10FDA Approved: DURYSTA — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Durysta (bimatoprost) from Allergan, Inc., to modify the product’s labeling and/or approved …
-
FDA approval · 2024-10-10FDA Approved: TIMOLOL HEMIHYDRATE — Original Application (Somerset Therapeutics, LLC)
FDA approved the original application for Timolol hemihydrate, a generic ophthalmic solution, from Somerset Therapeutics, LLC.
-
FDA approval · 2024-10-09FDA Approved: XELPROS — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for XELPROS (latanoprost) submitted by Sun Pharmaceutical Industries.
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Effect of Latanoprost on Optic Nerve Perfusion [Phase 1]
Phase 1 study evaluating the effect of latanoprost on optic nerve perfusion has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension [Phase 1]
This Phase 1 trial evaluated the safety and preliminary efficacy of OTX-TIC in participants with open-angle glaucoma or ocular hypertension,…
-
FDA approval · 2024-09-23FDA Approved: TRAVOPROST — Original Application (Somerset Therapeutics, LLC)
FDA approved an Original Application for Travoprost from Somerset Therapeutics, LLC (ANDA 217228), indicating approval of a generic Travopro…